Apotex Challenges Amgen Cancer Biologic Patent As Obvious
The maker of a competitor to the chemotherapy companion drugs Neulasta and Neupogen took aim at Amgen Inc.'s underlying patent on the biologics Wednesday at the Patent Trial and Appeal Board,...To view the full article, register now.
Already a subscriber? Click here to view full article